These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 32949827)

  • 1. Characteristics and response to crizotinib in lung cancer patients with MET amplification detected by next-generation sequencing.
    Li J; Wang Y; Zhang B; Xu J; Cao S; Zhong H
    Lung Cancer; 2020 Nov; 149():17-22. PubMed ID: 32949827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
    Wang W; Wang H; Lu P; Yu Z; Xu C; Zhuang W; Song Z
    J Transl Med; 2019 Feb; 17(1):52. PubMed ID: 30791921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group.
    Gürbüz M; Kiliçkap S; Bilici A; Karadurmuş N; Sezer A; Şendur MAN; Paydaş S; Artaç M; Fulden Yumuk P; Gürsoy P; Uysal M; Şenol Coşkun H; Tatli AM; Selçukbiricik F; Dişel U; Köksoy EB; Güven DC; Uğrakli M; Akkuş E; Yücel Ş; Erol C; Karakaya S; Şakalar T; Khanmammadov N; Paksoy N; Demirkazik A
    Medicine (Baltimore); 2022 Dec; 101(50):e32368. PubMed ID: 36550824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. De Novo MET Amplification in Chinese Patients With Non-Small-Cell Lung Cancer and Treatment Efficacy With Crizotinib: A Multicenter Retrospective Study.
    Song Z; Wang H; Yu Z; Lu P; Xu C; Chen G; Zhang Y
    Clin Lung Cancer; 2019 Mar; 20(2):e171-e176. PubMed ID: 30554986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to crizotinib in advanced ALK-rearranged non-small cell lung cancers with different ALK-fusion variants.
    Li Y; Zhang T; Zhang J; Li W; Yuan P; Xing P; Zhang Z; Chuai S; Li J; Ying J
    Lung Cancer; 2018 Apr; 118():128-133. PubMed ID: 29571990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient with EGFR-mutant lung cancer harboring de novo MET amplification successfully treated with gefitinib combined with crizotinib.
    Gu ZB; Liao LM; Yao GJ; Fang M; Huang L
    Curr Probl Cancer; 2021 Oct; 45(5):100702. PubMed ID: 33454089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression.
    Chen RL; Zhao J; Zhang XC; Lou NN; Chen HJ; Yang X; Su J; Xie Z; Zhou Q; Tu HY; Zhong WZ; Yan HH; Guo WB; Wu YL; Yang JJ
    BMC Cancer; 2018 Nov; 18(1):1171. PubMed ID: 30477470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers.
    Yang H; Zhou Z; Lin L; Yang M; Li C; Li Z; Yu X; Lizaso A; Han-Zhang H; Li B; Xiang J; Mao X; Xu Q; Zhang Y; Yang N
    Lung Cancer; 2020 Oct; 148():113-121. PubMed ID: 32889305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case report: HER2 amplification as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping.
    Ding G; Wang J; Ding P; Wen Y; Yang L
    Cancer Biol Ther; 2019; 20(6):837-842. PubMed ID: 30744539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.
    van Veggel B; de Langen AJ; Hashemi S; Monkhorst K; Rosenberg EH; Heideman DAM; Radonic T; Smit EF
    Lung Cancer; 2018 Oct; 124():130-134. PubMed ID: 30268451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Savolitinib versus crizotinib for treating MET positive non-small cell lung cancer.
    Miao K; Zhang X; Wang H; Si X; Zhang L
    Thorac Cancer; 2023 May; 14(13):1162-1170. PubMed ID: 36944506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crizotinib in Patients With MET-Amplified NSCLC.
    Camidge DR; Otterson GA; Clark JW; Ignatius Ou SH; Weiss J; Ades S; Shapiro GI; Socinski MA; Murphy DA; Conte U; Tang Y; Wang SC; Wilner KD; Villaruz LC
    J Thorac Oncol; 2021 Jun; 16(6):1017-1029. PubMed ID: 33676017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II, open-label, multicenter trial of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study.
    Shimokawa M; Nosaki K; Seto T; Ohashi K; Morise M; Horinouchi H; Sakakibara J; Murakami H; Yano S; Satouchi M; Matsumoto S; Goto K; Yoh K
    Trials; 2020 Mar; 21(1):298. PubMed ID: 32228679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
    Pruis MA; Geurts-Giele WRR; von der TJH; Meijssen IC; Dinjens WNM; Aerts JGJV; Dingemans AMC; Lolkema MP; Paats MS; Dubbink HJ
    Lung Cancer; 2020 Feb; 140():46-54. PubMed ID: 31862577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crizotinib for
    Tacar SY; Yilmaz M; Oz B; Tural D
    Tumori; 2022 Jun; 108(3):258-262. PubMed ID: 33849345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy.
    Wang Y; Tian P; Xia L; Li L; Han R; Zhu M; Lizaso A; Qin T; Li M; Yu B; Mao X; Han-Zhang H; He Y
    Lung Cancer; 2020 Aug; 146():165-173. PubMed ID: 32540560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis.
    Awad MM; Leonardi GC; Kravets S; Dahlberg SE; Drilon A; Noonan SA; Camidge DR; Ou SI; Costa DB; Gadgeel SM; Steuer CE; Forde PM; Zhu VW; Fukuda Y; Clark JW; Jänne PA; Mok T; Sholl LM; Heist RS
    Lung Cancer; 2019 Jul; 133():96-102. PubMed ID: 31200835
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK-rearranged non-small-cell lung cancer.
    Song P; Zhang F; Li Y; Yang G; Li W; Ying J; Gao S
    Cancer Med; 2019 Apr; 8(4):1551-1557. PubMed ID: 30843662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.
    Camidge DR; Dziadziuszko R; Peters S; Mok T; Noe J; Nowicka M; Gadgeel SM; Cheema P; Pavlakis N; de Marinis F; Cho BC; Zhang L; Moro-Sibilot D; Liu T; Bordogna W; Balas B; Müller B; Shaw AT
    J Thorac Oncol; 2019 Jul; 14(7):1233-1243. PubMed ID: 30902613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durable complete response after afatinib and crizotinib in an advanced non-small cell lung cancer patient with EGFR L861Q mutation and acquired MET amplification: a case report.
    Long Y; Zhang K; Li Y; Yu M; Zhu J; Huang M
    Ann Palliat Med; 2020 Sep; 9(5):3609-3613. PubMed ID: 32648452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.